<DOC>
	<DOCNO>NCT00392938</DOCNO>
	<brief_summary>RATIONALE : Imaging procedure , PET scan , may help doctor predict patient 's response treatment help plan best treatment . PURPOSE : This clinical trial study carbon-11 acetate fludeoxyglucose F 18 PET scan bone patient metastatic prostate cancer spread bone .</brief_summary>
	<brief_title>Carbon-11 Acetate Fludeoxyglucose F 18 PET Scan Bone Patients With Metastatic Prostate Cancer That Has Spread Bone</brief_title>
	<detailed_description>OBJECTIVES : Primary - Correlate pre-treatment 3-month post-treatment carbon-11 ( ^11C ) acetate fludeoxyglucose F 18 positron emission tomography ( ^18F-FDG PET ) image change clinical response measure patient bone-dominant metastatic prostate cancer . Secondary - Compare ^11C acetate ^18F-FDG PET scan result bone scintigraphy patient determine best predicts clinical response . - Correlate change ^11C acetate ^18F-FDG PET change prostate-specific antigen level . - Correlate change ^11C acetate ^18F-FDG PET clinical symptom parameter ( pain scale score analgesic usage scale ) . - Correlate ^11C acetate ^18F-FDG PET scan response clinical time progression . - Determine PET scan response predict duration progression-free survival . OUTLINE : This pilot study . Patients stratify accord hormone response ( sensitive [ stratum 1 ] v refractory [ stratum 2 ] ) . Patients undergo carbon-11 acetate fludeoxyglucose F 18 positron emission tomography image prior 3 month initiation either androgen-deprivation therapy ( stratum 1 ) docetaxel ( stratum 2 ) . Pain quality life assess baseline 3 month . Patients follow every 3 month 5 year . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Androgen Antagonists</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis prostate cancer , meet 1 follow criterion : Metastatic hormonesensitive disease prior initiation firstline androgendeprivation therapy meet follow criterion : Histologic confirmation original diagnosis Hormonesensitive define progressive disease absence androgendeprivation therapy Presence ≥ 3 convince bone metastasis , define bone scintigraphy , CT scan ( MRI indicate ) , plain xray Metastatic hormonerefractory disease prior initiation firstline chemotherapy regimen include docetaxel meet follow criterion : Histologic confirmation original diagnosis Hormonerefractory define development advancement metastatic disease castrate testosterone level ( total testosterone &lt; 20 ng/dL ) Presence ≥ 3 convince bone metastasis , define bone scintigraphy , CT scan ( MRI indicate ) , plain xray Must castrate testosterone level ( &lt; 20 ng/dL ) orchiectomy undergoing maintenance luteinizing hormonereleasing hormone agonist Outside window potential antiandrogen withdrawal response ( either decline prostatespecific antigen objective response image ) PATIENT CHARACTERISTICS : Life expectancy &gt; 12 week No serious underlie medical condition would otherwise impair patient 's ability receive treatment undergo image study No condition would alter patient 's mental status , prohibit basic understanding and/or authorization inform consent Able lie still image Weight ≤ 300 lbs PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 6 week since prior bicalutamide nilutamide At least 4 week since prior flutamide , ketoconazole , diethylstilbestrol , estradiol More 4 week since prior bisphosphonate therapy More 4 week since prior radiotherapy bone More 4 week since prior radiopharmaceutical treatment bone No concurrent radiotherapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>bone metastasis</keyword>
</DOC>